Clinical Trial

Bioequivalence Study to Compare Empagliflozin/ Metformin 25 mg/ 1000 mg Extended-Release Tablet Versus Synjardy XR Tablets 25mg/1000mg

Completed Phase 1
View on ClinicalTrials.gov →
Summary
An open label, randomized, two-period, two treatment, two-sequence, crossover, balanced, single dose oral bioequivalence study to compare Empagliflozin / Metformin 25 mg/ 1000 mg Extended-Release Tablet versus Synjardy XR tablets 25mg/1000mg in healthy subject in fasting condition.
Trial Details
NCT Number NCT07694115
Lead Sponsor Humanis Saglık Anonim Sirketi
Conditions Type 2 Diabetes Mellitus (T2DM)
Enrollment 40 participants
Start Date 2026-05-07
Primary Completion 2026-06-29 (estimated)
Study Completion 2026-07-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-09